Reported 3 days ago
Sangamo Therapeutics saw its stock plunge by as much as 67% following Pfizer Inc.'s decision to end their collaboration on a gene therapy for hemophilia A. Despite the therapy showing promise in late-stage trials, Sangamo's CEO expressed surprise and disappointment at Pfizer's withdrawal, which came after the company had anticipated significant milestone payments. Sangamo is now exploring alternatives for the drug's development amid ongoing liquidity concerns.
Source: YAHOO